This understanding led to multiple preclinical studies which demonstrated the effectiveness of rapamycin, an mTORC1 inhibitor, in multiple animal models of TSC [5]–[11], which led to rapid clinical translation, and demonstration that rapamycin has clinical benefit for TSC kidney, lung, and brain tumors [12]–[15]. The gene discussed is TSC1; the disease is brain neoplasm.